Literature DB >> 15213152

Nasal delivery of antigen with the B subunit of Escherichia coli heat-labile enterotoxin augments antigen-specific T-cell clonal expansion and differentiation.

Maria Apostolaki1, Neil A Williams.   

Abstract

Escherichia coli heat-labile enterotoxin has unique immunogenic and adjuvant properties when administered mucosally to mice. These properties have revealed the potential for its use in the development of mucosal vaccines, an area of increasing interest. However, the inherent toxicity mediated by the A subunit precludes its widespread use. This problem has led to attempts to dissociate toxicity from adjuvant function by use of the B subunit. The ability of the B subunit of E. coli heat-labile enterotoxin (EtxB) to enhance responses against antigens coadministered intranasally is demonstrated here with the use of the DO11.10 adoptive-transfer model, in which ovalbumin (OVA)-specific adoptively transferred T cells can be monitored directly by flow cytometry. Intranasal delivery of OVA with EtxB resulted in increased T-cell proliferative and systemic antibody responses against antigens. The increased Th2 cytokine production detected following in vitro restimulation of splenocyte and cervical lymph node (CLN) cells from the immunized mice correlated with increased OVA-specific immunoglobulin G1 antibody production. Flow cytometric analysis of T cells from mice early after immunization directly revealed the ability of EtxB to support antigen-specific clonal expansion and differentiation. Furthermore, while responses were first detected in the CLNs, they rapidly progressed to the spleen, where they were further sustained. Examination of CD69 expression on dividing cells supported the notion that activation induced by the presence of antigens is not sufficient to drive T-cell differentiation. Furthermore, a lack of CD25 expression on dividing cells suggested that EtxB-mediated T-cell clonal expansion may occur without a sustained requirement for interleukin 2.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15213152      PMCID: PMC427462          DOI: 10.1128/IAI.72.7.4072-4080.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  56 in total

1.  Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming.

Authors:  M C Gagliardi; F Sallusto; M Marinaro; A Langenkamp; A Lanzavecchia; M T De Magistris
Journal:  Eur J Immunol       Date:  2000-08       Impact factor: 5.532

2.  Generation of anergic and potentially immunoregulatory CD25+CD4 T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen.

Authors:  K M Thorstenson; A Khoruts
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

3.  Regulation of house dust mite responses by intranasally administered peptide: transient activation of CD4+ T cells precedes the development of tolerance in vivo.

Authors:  G F Hoyne; B A Askonas; C Hetzel; W R Thomas; J R Lamb
Journal:  Int Immunol       Date:  1996-03       Impact factor: 4.823

4.  T-cell activation and receptor downmodulation precede deletion induced by mucosally administered antigen.

Authors:  J M Benson; K A Campbell; Z Guan; I E Gienapp; S S Stuckman; T Forsthuber; C C Whitacre
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

5.  Protective mucosal immunity to ocular herpes simplex virus type 1 infection in mice by using Escherichia coli heat-labile enterotoxin B subunit as an adjuvant.

Authors:  C M Richards; A T Aman; T R Hirst; T J Hill; N A Williams
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

Review 6.  Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.

Authors:  M Yamamoto; J R McGhee; Y Hagiwara; S Otake; H Kiyono
Journal:  Scand J Immunol       Date:  2001-03       Impact factor: 3.487

Review 7.  Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.

Authors:  M Pizza; M M Giuliani; M R Fontana; E Monaci; G Douce; G Dougan; K H Mills; R Rappuoli; G Del Giudice
Journal:  Vaccine       Date:  2001-03-21       Impact factor: 3.641

8.  Escherichia coli heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its vlosely related homologue, the B subunit of cholera toxin.

Authors:  D G Millar; T R Hirst; D P Snider
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

9.  Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections.

Authors:  H Jakobsen; D Schulz; M Pizza; R Rappuoli; I Jónsdóttir
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

10.  Migration and function of antigen-primed nonpolarized T lymphocytes in vivo.

Authors:  G Iezzi; D Scheidegger; A Lanzavecchia
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

View more
  4 in total

1.  CpG adjuvant enhances the mucosal immunogenicity and efficacy of a Treponema pallidum DNA vaccine in rabbits.

Authors:  Feijun Zhao; Shuangquan Liu; Xiaohong Zhang; Jian Yu; Tiebing Zeng; Weiming Gu; Xunyu Cao; Xi Chen; Yimou Wu
Journal:  Hum Vaccin Immunother       Date:  2013-04-01       Impact factor: 3.452

2.  The B subunit of Escherichia coli heat-labile toxin alters the development and antigen-presenting capacity of dendritic cells.

Authors:  Jing Ji; Kristin L Griffiths; Peter J Milburn; Timothy R Hirst; Helen C O'Neill
Journal:  J Cell Mol Med       Date:  2015-07-01       Impact factor: 5.310

3.  Production and purification of immunologically active core protein p24 from HIV-1 fused to ricin toxin B subunit in E. coli.

Authors:  Alberto J Donayre-Torres; Ernesto Esquivel-Soto; María de Lourdes Gutiérrez-Xicoténcatl; Fernando R Esquivel-Guadarrama; Miguel A Gómez-Lim
Journal:  Virol J       Date:  2009-02-06       Impact factor: 4.099

4.  The Quest for an HIV-1 Vaccine Adjuvant: Bacterial Toxins as New Potential Platforms.

Authors:  Toufic O Nashar
Journal:  J Clin Cell Immunol       Date:  2014-07-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.